1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
FDA Broad Agency Announcement (BAA) for Antimicrobial Resistance Research is sponsored by FDA Center for Drug Evaluation and Research (CDER). FDA Broad Agency Announcement (BAA) for Antimicrobial Resistance Research is a contract opportunity from the FDA Center for Drug Evaluation and Research (CDER) that funds basic and applied research and development to advance regulatory science and innovation in antimicrobial res…
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
## FY26 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science ## FY26 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science Contract Opportunity Type Contract Line Item Number ##### Feb 24, 2026 5:00 PM EST ##### Jan 16, 2026 7:42 AM EST ##### HEALTH AND HUMAN SERVICES, DEPARTMENT OF ##### FOOD AND DRUG ADMINISTRATION ##### FDA Office of Acquisitions and Grants Services ##### AJ11 - GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; BASIC RESEARCH ##### 541714 - Research and Development in Biotechnology (except Nanobiotechnology) Amendment 03 - Updated the announcement document to version 2.
0. Changes are highlighted throughout the document. Amendment 02 - Save the date!
the FY26 Virtual BAA day - 20 January 2026! https://www. fda.
gov/science-research/advancing-regulatory-science/2026-fda-broad-agency-announcement-day-01202026 Amendment 01 - Updated the announcement document to version 2. 0. Changes are highlighted throughout the document.
In accordance with FAR 6. 102(d)(2) and 35. 016, the US Food and Drug Administration (FDA) solicits for the acquisition of basic and applied research and development proposals to support regulatory science and innovation through this Broad Agency Announcement (BAA).
Research and development activities acquired under this BAA are intended to advance scientific knowledge in specific research areas as well as sub areas of interest defined within the BAA that serve the FDA in accomplishing its mission to protect and promote the health of our nation. Proposals submitted under this announcement are not limited solely to the PSC code "AJ11" specified in this announcement.
FDA funds extramural research through an agency-wide Broad Agency Announcement (BAA) for research and development to support regulatory science and innovation. No links have been added to this opportunity.
According to the current listing, eligibility includes: Academic institutions, research organizations, and private industry. Confirm the full requirements in the official notice before applying.
FDA Broad Agency Announcement (BAA) for Antimicrobial Resistance Research is funded by FDA Center for Drug Evaluation and Research (CDER). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articleARPA-H's FASTPASS program targets a public-health blind spot: substandard and contaminated drugs that are only caught after patients are exposed. It funds through-package chemical sensing (TA1 SAMPLE) and the analytics to act on it (TA2 DETECT). The solicitation posts to SAM.gov in mid-August 2026, with a virtual Proposer Workshop on August 24 and registration closing August 20. Here is what FASTPASS funds, why the timing matters, and how to position a cross-disciplinary team.
Read articleARPA-H PROSPR program funds seven research teams testing rapamycin, semaglutide, and novel compounds to extend healthspan. A deep analysis of the science, the money, and what it means for the field.
Read article